RedHill Biopharma (RDHL) Consolidated Net Income (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Consolidated Net Income data on file, last reported at $80.5 million in Q2 2023.

• Consolidated Net Income for Q2 2023 came in at $80.5 million, up 1116.61% year-over-year; the trailing twelve-month figure through Dec 2024 was $80.5 million (up 1528.12% YoY), and the FY2025 annual result was $7.7 million, up 188.68% from the prior year.
• Consolidated Net Income grew to $80.5 million in Q2 2023 per RDHL's latest filing, from -$7.9 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at $80.5 million in Q2 2023 and troughed at -$145.3 million in Q4 2021.
• A 5-year average of -$248444.4 and a median of $11.2 million in 2019 frame the typical range for Consolidated Net Income.
• The sharpest annual moves came in 2021 and 2023: Consolidated Net Income plunged 1058.54% in 2021, then soared 1116.61% in 2023.
• A 5-year view of Consolidated Net Income shows it stood at $11.6 million in 2019, then surged by 30.9% to $15.2 million in 2020, then sank by 1058.54% to -$145.3 million in 2021, then jumped by 46.15% to -$78.2 million in 2022, then soared by 202.92% to $80.5 million in 2023.
• Business Quant data shows RDHL's Consolidated Net Income at $80.5 million in Q2 2023, -$7.9 million in Q1 2023, and -$78.2 million in Q4 2022.